Get the Stockscreener App
108.58
0.58%
0.63
Pre-market:
109.00
0.42
+0.39%
Celcuity Inc stock is traded at $108.58, with a volume of 1.14M.
It is up +0.58% in the last 24 hours and up +23.00% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$107.95
Open:
$107.91
24h Volume:
1.14M
Relative Volume:
0.89
Market Cap:
$5.30B
Revenue:
-
Net Income/Loss:
$-192.89M
P/E Ratio:
-27.86
EPS:
-3.8976
Net Cash Flow:
$-172.97M
1W Performance:
+5.91%
1M Performance:
+23.00%
6M Performance:
+3.39%
1Y Performance:
+687.38%
1-Day Range:
$106.20
$111.04
1-Week Range:
$101.19
$111.04
52-Week Range:
$13.14
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
108.58 | 5.10B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Price to earnings forward of Celcuity Inc. – NASDAQ:CELC - TradingView
Price to sales forward of Celcuity Inc. – DUS:7VR - TradingView
Celcuity Inc.(NasdaqCM: CELC) dropped from Russell 2000 Value Benchmark - marketscreener.com
Celcuity Inc.(NasdaqCM: CELC) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
How Does Celcuity’s (CELC) Russell Index Exit Reframe Its Gedatolisib-Centered Investment Story? - simplywall.st
Celcuity Inc.(NasdaqCM: CELC) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Celcuity Inc.(NasdaqCM: CELC) dropped from Russell Microcap Index - marketscreener.com
Celcuity Inc.(NasdaqCM: CELC) dropped from Russell 3000E Index - marketscreener.com
Enterprise value to revenue forward of Celcuity Inc. – NASDAQ:CELC - TradingView
Enterprise value to EBITDA forward of Celcuity Inc. – NASDAQ:CELC - TradingView
Enterprise value to EBITDA forward of Celcuity Inc. – MUN:7VR - TradingView
Enterprise value to revenue forward of Celcuity Inc. – MUN:7VR - TradingView
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Enterprise value to EBIT forward of Celcuity Inc. – MUN:7VR - TradingView
Price to sales forward of Celcuity Inc. – MUN:7VR - TradingView
Price to book forward of Celcuity Inc. – MUN:7VR - TradingView
Celcuity Inc. Actuals & Estimates (NASDAQ:CELC) - TradingView
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
CELC Forecast — Price Target — Prediction for 2027 - TradingView
A2JAAX Forecast — Price Target — Prediction for 2027 - TradingView
Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC) - Kavout | AI
Celcuity Heads Toward A Major Regulatory Catalyst Next Month - RTTNews
Celcuity’s Breakout Run Now Hangs On An FDA Call - Finimize
Celcuity Inc (CELC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celcuity Inc (CELC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celcuity Inc (CELC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celcuity Inc (CELC) Institutional Confidence - TradingKey
Celcuity Inc (CELC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celcuity Inc (CELC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celcuity Inc (CELC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Celcuity Inc (CELC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celcuity Inc (CELC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celcuity shares fall despite strong phase 3 breast cancer trial data (CELC) - MSN
Should Celcuity’s $500 Million Convertible Notes and VIKTORIA-1 Data Shift the CELC Investment Thesis Require Action From Celcuity (CELC) Investors? - simplywall.st
Trading the Move, Not the Narrative: (CELC) Edition - Stock Traders Daily
CELC News | CELCUITY INC (NASDAQ:CELC) - ChartMill
Guggenheim Initiates Coverage of Celcuity (CELC) with Buy Recommendation - MSN
CELC stock records worst day ever after late-stage breast cancer trial results — what’s driving the selloff? - MSN
ACT CAPITAL MANAGEMENT, LLC's Celcuity Inc(CELC) Holding History - GuruFocus
Celcuity raises $500M in upsized 0.25% convertible notes sale - MSN
TD Asset Management Inc Has $9.73 Million Stake in Celcuity, Inc. $CELC - MarketBeat
CELC6416934 Bond Coupon Analysis — Rate & Payments - TradingView
Director at Celcuity (CELC) receives 1,530-share stock grant and reports holdings - Stock Titan
Celcuity Refinances Debt with New Convertible Notes Offering - TipRanks
Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million - TradingView
Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC - MarketBeat
BNP Paribas Financial Markets Sells 36,648 Shares of Celcuity, Inc. $CELC - MarketBeat
CELC6416934 Bond Price and Chart — FINRA:CELC6416934 - TradingView
Preferred dividends of Celcuity Inc. – HAM:7VR - TradingView
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celcuity Inc Stock (CELC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dalvey David | Director |
May 04 '26 |
Sale |
140.68 |
25,000 |
3,517,000 |
65,000 |
| Buller Richard E | Director |
May 04 '26 |
Option Exercise |
5.10 |
9,000 |
45,900 |
15,760 |
| Buller Richard E | Director |
May 04 '26 |
Sale |
140.46 |
9,000 |
1,264,181 |
6,760 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):